RareGen

RareGen is a biopharmaceutical firm that develops and commercializes therapeutics for the treatment of pulmonary arterial hypertension. Read more

RareGen

RareGen is a biopharmaceutical firm that develops and commercializes therapeutics for the treatment of pulmonary arterial hypertension. Read more

Damian DeGoa's photo - CEO of RareGen

CEO

Damian DeGoa

CEO Approval Rating

90/100

Founded:

2018

RAREGEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Pulmokine is the top competitor of RareGen. Pulmokine is headquartered in Rensselaer, New York, and was founded in 2007. Pulmokine competes in the Pharmaceuticals field. Pulmokine generates 30% the revenue of RareGen.

Amicus is perceived as one of RareGen's biggest rivals. Amicus was founded in Philadelphia, Pennsylvania} in 2002. Like RareGen, Amicus also operates in the Pharmaceuticals industry. Compared to RareGen, Amicus generates $224.6M more revenue.

Ultragenyx is seen as one of RareGen's top competitors. Ultragenyx is a Public company that was founded in Novato, California in 2010. Like RareGen, Ultragenyx also works within the Pharmaceuticals industry. Ultragenyx has 859 more employees vs. RareGen.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 34 a good estimate for RareGen's Employee count?

RareGen Acquisitions

No recent acquisitions found related to RareGen

RareGen Funding History

No recent funding data found related to RareGen

RareGen Investments

No recent investments found related to RareGen

RareGen News

July 20, 2020Pharamceutical Technology

Liquidia's recent announcement to acquire RareGen strengthens its position in the PAH space

On 29 June, Liquidia Technologies announced its plans to acquire RareGen, which specialises in strate... See more »
July 5, 2020Charlotteraleigh Citybizlist

Liquidia to Acquire RareGen

Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused o... See more »

Social Media

RareGen Headquarters

1000 Park Forty Plaza

Durham, North Carolina27713

Driving Directions »

Trending Companies

RareGen Summary

ABOUT

Overview

RareGen is a biopharmaceutical firm that develops and commercializes therapeutics for the treatment of pulmonary arterial hypertension. RareGen was founded in 2018. RareGen's headquarters is located in Durham, North Carolina, USA 27713. RareGen's CEO...

CEO

RareGen's CEO, Damian DeGoa, currently has an approval rating of 90%. RareGen's primary competitors are Pulmokine, Amicus & Ultragenyx.

Website

raregenllc.com

Frequently Asked Questions about RareGen

  1. When was RareGen founded?

    RareGen was founded in 2018
  2. Who is RareGen's CEO?

    RareGen's CEO is Damian DeGoa
  3. How much revenue does RareGen generate?

    RareGen generates $14.5M in revenue
  4. How much funding does RareGen have?

    RareGen has historically raised $0 in funding
  1. Where is RareGen's headquarters?

    RareGen's headquarters is in Durham North Carolina, USA
  2. How many employees does RareGen have?

    RareGen has 34 employees
  3. What sector does RareGen operate in?

    RareGen is in Pharmaceuticals, Biotechnology
  4. Who are RareGen's competitors?

    RareGen's top competitors are Pulmokine, Amicus, Ultragenyx